Status:
COMPLETED
High Intensity Interval Training in Fibrotic Interstitial Lung Disease
Lead Sponsor:
Monash University
Conditions:
Fibrotic Interstitial Lung Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The fibrotic interstitial lung diseases (fILD) is a group of debilitating chronic lung conditions that are characterised by scarring of lung tissue, dyspnoea on exertion and significant physical impai...
Detailed Description
Interstitial lung disease (ILD) is a chronic lung condition characterized by scarring of lung tissue. This stiffening of the lungs impairs breathing and reduces the amount of oxygen being delivered th...
Eligibility Criteria
Inclusion
- Diagnosis of fibrotic interstitial lung disease (fILD)
- Able to read and speak English
Exclusion
- Resting oxygen saturation (SpO2) is \< 85%
- Severe pulmonary hypertension (WHO class IV)
- Attendance at Pulmonary rehabilitation (PR) within last 12 months
- Comorbidities which preclude exercise training
- History of syncope on exertion
- Significant cognitive impairment
- Anticipated transplant or death within the duration of the study period
Key Trial Info
Start Date :
July 17 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 4 2024
Estimated Enrollment :
131 Patients enrolled
Trial Details
Trial ID
NCT03800914
Start Date
July 17 2019
End Date
December 4 2024
Last Update
July 8 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia, 2050
2
Prince Charles Hospital
Brisbane, Queensland, Australia, 4032
3
Austin Health
Heidelberg, Victoria, Australia, 3084
4
Alfred Health
Melbourne, Victoria, Australia, 3004